APAnthony G. Pacholko

Anthony G. Pacholko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anthony G. Pacholko has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hypertension-induced neurovascular and cognitive dysfunction at single-cell resolution

    by Samantha M. Schaeffer, Anthony G. Pacholko, Monica M. Santisteban, Sung Ji Ahn, Gianfranco Racchumi, Gang Wang, Laibaik Park, Giuseppe Faraco, Josef Anrather, Costantino Iadecola


  • Top Cited Papers

    Hypertension, Neurodegeneration, and Cognitive Decline

    by Anthony Pacholko, Costantino Iadecola

    Elevated blood pressure is a well-established risk factor for age-related cognitive decline. Long linked to cognitive impairment on vascular bases, increasing evidence suggests a potential association of hypertension with the neurodegenerative pathology underlying Alzheimer disease. Hypertension is well known to disrupt the structural and functional integrity of the cerebral vasculature. However, the mechanisms by which these alterations lead to brain damage, enhance Alzheimer pathology, and promote cognitive impairment remain to be established. Furthermore, critical questions concerning whether lowering blood pressure by antihypertensive medications prevents cognitive impairment have not been answered. Recent developments in neurovascular biology, brain imaging, and epidemiology, as well as new clinical trials, have provided insights into these critical issues. In particular, clinical and basic findings on the link between neurovascular dysfunction and the pathobiology of neurodegeneration have shed new light on the overlap between vascular and Alzheimer pathology. In this review, we will examine the progress made in the relationship between hypertension and cognitive impairment and, after a critical evaluation of the evidence, attempt to identify remaining knowledge gaps and future research directions that may advance our understanding of one of the leading health challenges of our time.


  • Open Access

    Different pharmacokinetics of lithium orotate inform why it is more potent, effective, and less toxic than lithium carbonate in a mouse model of mania

    by Anthony G. Pacholko, Lane K. Bekar

    Background Lithium carbonate (LiCO) is a mainstay treatment option for the prevention of mood-episode recurrences in bipolar disorder (BD). Unfortunately, the narrow therapeutic index of LiCO is associated with common thyroid and kidney complications that lead to high rates of non-compliance. Lithium orotate (LiOr) is an alternative compound that is suggested to possess uptake properties that would allow for reduced dosing to mitigate toxicity and compliance concerns. Methods Dose responses were established for LiOr and LiCO in male and female mice using an amphetamine-induced hyperlocomotion (AIH) murine (C57BL/6) model (n = 5-11); AIH captures manic elements of BD and is sensitive to a dose-dependent lithium blockade. These studies were followed by an examination of the relative toxicities of LiOr and LiCO over 14 consecutive daily administrations (n = 5-7). Results A partial block of AIH was maintained by LiCO at doses of 15 mg/kg or greater in males and 20 mg/kg or greater in females. In contrast, a near-complete blockade was observed for LiOr concentrations equal to or exceeding 1.5 mg/kg in both males and females, indicating improved efficacy and potency. Prior application of polyethylene glycol-400 completely blocked the effects of LiOr on AIH while sparing LiCO, suggesting differences in transport between the two compounds. LiCO, but not LiOr, elicited polydipsia in both sexes, elevated serum creatinine levels in males, and increased serum TSH expression in females. Conclusions LiOr demonstrates superior efficacy, potency, and tolerability to LiCO in both male and female mice as a result of select transport-mediated uptake.


  • Open Access

    Lithium orotate: A superior option for lithium therapy?

    by Anthony G. Pacholko, Lane K. Bekar

    Bipolar disorder (BD) poses a significant public health concern, with roughly one‐quarter of sufferers attempting suicide. BD is characterized by manic and depressive mood cycles, the recurrence of which can be effectively curtailed through lithium therapy. Unfortunately, the most frequently employed lithium salt, lithium carbonate (Li2CO3), is associated with a host of adverse health outcomes following chronic use: these unwanted effects range from relatively minor inconveniences (e.g., polydipsia and polyuria) to potentially major complications (e.g., hypothyroidism and/or renal impairment). As these undesirable effects can limit patient compliance, an alternative lithium compound with a lesser toxicity profile would dramatically improve treatment efficacy and outcomes. Lithium orotate (LiC5H3N2O4; henceforth referred to as LiOr), a compound largely abandoned since the late 1970s, may represent such an alternative. LiOr is proposed to cross the blood–brain barrier and enter cells more readily than Li2CO3, which will theoretically allow for reduced dosage requirements and ameliorated toxicity concerns. This review addresses the controversial history of LiOr, complete with discussions of experimental and clinical efficacy, putative mechanisms of action, adverse effects, and its potential future in therapy.


  • Open Access

    Acute inflammatory events attenuate high-sucrose diet-induced neurodegenerative processes in reproductively normal female wild-type mice

    by Anthony G. Pacholko, Lane K. Bekar

    It is known that diabetic and chronic inflammatory conditions can increase the risk of Alzheimer’s disease (AD)-like neurodegeneration in isolation. As certain elements of the diabetic/pre-diabetic state may sensitize the brain to inflammatory insult ( i.e . excess glucocorticoid activity), there is reason to believe that obesogenic and inflammatory factors may accelerate neurodegeneration in a synergistic manner. Also, given that most AD research utilizes male animal models despite increased prevalence of AD among women, we sought to characterize elements of the established (in males) high-sucrose model of neurodegeneration, for the first time, in reproductively normal (pre-menopausal) female mice. A high-sucrose diet (20% of the drinking water) was combined with systemic intraperitoneal lipopolysaccharide (LPS) injections (0.1 mg/kg; 1x/month over 3 months) over seven months in reproductively normal female wild-type mice (C57Bl/6; n=10/group). Although a deleterious effect was hypothesized, low-dose LPS proved to protect against high sucrose diet-induced pathologies in female wild-type mice. Results from our high-sucrose group confirmed that a high-sucrose diet is a mild model of neurodegeneration in wild-type females, as evidenced by exaggerated glucocorticoid expression, spatial learning deficits, irregularities within the insulin pathway, and increased β-amyloid production and Tau phosphorylation. While LPS had little to no effect in isolation, it exerted a protective influence when added to animals sustained on a high-sucrose diet. Corticosterone homeostasis, and levels of amyloid-β (Aβ) and pTau were rescued following addition of LPS. The work presented supports a high-sucrose diet as a model of mild neurodegeneration in female mice and highlights a protective role for transient inflammation against dietary-insult that may be sex dependent.


  • The locus coeruleus neurotoxin, DSP4, and/or a high sugar diet induce behavioral and biochemical alterations in wild-type mice consistent with Alzheimers related pathology

    by Pooja Choudhary, Anthony G. Pacholko, Josh Palaschuk, Lane K. Bekar

    Alzheimer’s disease (AD) is the sixth leading cause of death in the United States where it is estimated that one in three seniors dies with AD or another dementia. Are modern lifestyle habits a contributing factor? Increased carbohydrate (sugar) consumption, stress and disruption of sleep patterns are quickly becoming the norm rather than the exception. Interestingly, seven months on a non-invasive high sucrose diet (20% sucrose in drinking water) has been shown to induce behavioral, metabolic and pathological changes consistent with AD in wild-type mice. As chronic stress and depression are associated with loss of locus coeruleus (LC) noradrenergic neurons and projections (source of anti-inflammatory and trophic factor control), we assessed the ability for a selective LC neurotoxin (DSP4) to accelerate and aggravate a high-sucrose mediated AD-related phenotype in wild-type mice. Male C57/Bl6 mice were divided into four groups: 1) saline injected, 2) DSP4 injected, 3) high sucrose drinking water (20%) or 4) DSP4 injected and high sucrose drinking water. We demonstrate that high sucrose consumption and DSP4 treatment promote an early-stage AD-related phenotype after only 3–4 months, as evidenced by elevated fecal corticosterone, increased despair, spatial memory deficits, increased AChE activity, elevated NO production, decreased pGSK3β and increased pTau. Combined treatment appears to accelerate and aggravate pathological processes consistent with Alzheimer disease and dementia. Developing a simple model in wild-type mice will highlight environmental and lifestyle factors that need to be addressed to slow, prevent or even reverse the rising trend in dementia patient numbers and cost.